Shares of Wave Life Sciences WVE surged 53.4% on Tuesday after the company announced positive interim data from a mid-stage study evaluating its investigational candidate, WVE-N531, to treat boys ...

Wave Life Sciences (NASDAQ:WVE) added ~8% premarket Tuesday after the RNA therapeutics company announced interim data from a Phase 2 trial for WVE-N531, an experimental therapy for a neuromuscular ...

Interim phase II data of Wave Life Sciences Ltd.’s oligonucleotide, WVE-N531, revealed “impressive” dystrophin expression, solid safety and the potential for once-monthly dosing for boys with Duchenne ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Wave Life Sciences (WVE – Research Report) today and set a price target of $13.00. Eric Joseph has given his Buy rating due to a ...

On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 ...

Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531, showing >5% dystrophin production. The safety profile of WVE-N531 is ...

The mean exon skipping was 57%. WVE-N531 was detected in myocyte nuclei in all participants and myogenic stem cells in most participants. Myogenic stem cells are the progenitor cells for new ...

This was contained in the World Bank’s Food Security Update Report released recently while highlighting that countries like Nigeria, Ethiopia and Yemen have seen a significant rise in the number ...

WVE expects to share 48-week data from the complete FORWARD-53 study of WVE-N531 for DMD in the first quarter of 2025 and receive feedback from regulators on a pathway to accelerated approval.

The 5.5% figure is derived from an analysis that excluded one non-ambulatory patient who had much lower levels of dystrophin after receiving Wave’s oligonucleotide WVE-N531. Wave’s result is ...